271: Racing for gene therapy, a pioneering approval, & startups in the lurch
The Readout Loud
00:00
Approval and Pricing of Medicine for Rare Disease
Discussion on the approval and pricing of MIPSEN, a medicine for a rare disease, costing $624,000 per year, with ongoing research on its benefits and regulatory flexibility due to disease severity and input from patient advocacy groups.
Transcript
Play full episode
